- In December 2024, CORE Kidney has partnered with Boehringer Ingelheim and Eli Lilly at the 2025 Tournament of Roses Parade to emphasize the importance of two tests—blood and urine—for those at risk of kidney disease, particularly individuals with type 2 diabetes or high blood pressure, which contribute to most CKD cases. This collaboration will enhance awareness and position CORE Kidney as a key player in promoting early detection and prevention of CKD
- In November 2024, Mitsui Chemicals, Inc. has invested in Rege Nephro Co., Ltd. through the 321FORCE Global Innovation Fund L.P. Rege Nephro, focused on R&D for kidney disease drugs, will benefit from this investment by accelerating the development of its innovative treatments
- In October 2024, Rege Nephro Co., Ltd. has secured approximately USD17 million in new Series B funding, bringing its total funding to USD30 million. The round was led by strategic investors such as DCI Partners Co., Ltd., JIC Venture Growth Investments, and several others. The funds will advance Phase II clinical trials for RN-014, a promising treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and support preclinical trials for RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy. This funding will enable Rege Nephro to accelerate the development of its innovative treatments, bringing them closer to improving outcomes for patients with kidney diseases
- In May 2024, Premier, Inc. has formed a strategic partnership with AstraZeneca for the Uncover CKD - Care Collective initiative, aimed at identifying undiagnosed CKD patients, raising awareness among healthcare providers, and assisting U.S. health systems in improving CKD diagnosis and management strategies. This collaboration will enhance Premier's role in advancing CKD care and expand its influence in healthcare systems through effective early detection and management solutions
- In January 2024, XORTX Therapeutics has submitted a new patent for treating chronic kidney disease (CKD), focusing on safer and more effective oral and sublingual formulations of xanthine oxidase inhibitors (XOI) for conditions such as ADPKD, diabetic nephropathy, and others. This patent will help the company protect its innovative treatment strategies and enhance its portfolio in the kidney disease market
